Back to results
US 10,137,155 B2Granted
Compositions and methods for inhibition of lineage specific antigens
AssigneeThe Trustees of Columbia University in the City of New York
InventorsSiddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
Claims20
A method of treating a hematopoietic malignancy, comprising administering to a subject in need thereof:
- (i) an effective amount of an agent targeting a lineage-specific cell-surface antigen, wherein the agent comprises an antigen-binding fragment that binds the lineage-specific cell-surface antigen, wherein the lineage-specific cell-surface antigen is CD33 or CD19;
- and wherein the agent is an immune cell expressing a chimeric receptor that comprises the antigen-binding fragment;
- and
- (ii) a population of hematopoietic cells, wherein the hematopoietic cells are genetically-engineered such that the gene encoding the lineage specific cell-surface antigen that is targeted by the antigen-binding fragment of (i) is engineered to reduce or eliminate the expression of the lineage-specific cell-surface antigen that is targeted by the antigen-binding fragment of (i);
- and
- wherein the immune cell set forth in (i) is different from the population of hematopoietic cells set forth in (ii).
3 more elements
Dependencies are inferred from the claim text.